Home›Clinical trials›South Carolina

GLP-1 clinical trials in South Carolina: 19 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

19 GLP-1 clinical trials are recruiting at 29 sites in 10 cities across South Carolina. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in South Carolina

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    2 sites in South Carolina

  2. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in South Carolina

  3. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    3 sites in South Carolina

    • Medical University of South Carolina, Charleston. 833-602-2368
    • ObjectiveHealth-Columbia Digestive Health Research, Columbia. 833-602-2368
    • Palmetto Clinical Research, Summerville. 833-602-2368

  4. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    2 sites in South Carolina

    • ObjectiveHealth-Columbia Digestive Health Research, Columbia. 833-602-2368
    • Palmetto Clinical Research, Summerville. 833-602-2368

  5. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    2 sites in South Carolina

    • Coastal Pediatric Associates, Charleston
    • Medical University of South Carolina Children Hospital - PIN, Charleston

  6. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    2 sites in South Carolina

    • Prisma Health-Ped Endo, Greenville
    • Coastal Carolina Research Ctr, North Charleston

  7. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living

    Phase 3. Run by Kailera. Registry number NCT07284979.

    A study testing whether an investigational medicine from Kailera, KAI-9531, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in South Carolina

    • Kailera Clinical Site, North Charleston
    • Kailera Clinical Site, Spartanburg

  8. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    2 sites in South Carolina

    • Velocity Clinical Research-Gaffney, Gaffney
    • Spartanburg Medical Research, Spartanburg

  9. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in South Carolina

    • Research Site, Myrtle Beach
    • Research Site, North Charleston

  10. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    2 sites in South Carolina

  11. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in South Carolina

    • Gastroenterology Associates - Patewood, Greenville. 864-451-5026

  12. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in South Carolina

    • Gastroenterology Associates - Patewood, Greenville. 864-451-5026

  13. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    1 site in South Carolina

    • Columbia Digestive Health Research, Columbia

  14. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07770841.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in South Carolina

    • Spartanburg Medical Research, Spartanburg

  15. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in South Carolina

  16. Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

    Phase 2. Run by T. John Winhusen, PhD. Registry number NCT06651177.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with opioid use disorder cut down on opioids.

    Who can join. Adults 18+, have opioid use disorder, BMI 23+.

    1 site in South Carolina

  17. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07668388.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in South Carolina

    • Monroe Biomedical Research, LLC, North Charleston

  18. Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse

    Phase 1. Run by Novo Nordisk A/S. Registry number NCT07607587.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in South Carolina

    • Coastal Carolina Research Ctr, North Charleston

  19. GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound

    Run by Medical University of South Carolina. Registry number NCT07251803.

    A study listed on ClinicalTrials.gov.

    1 site in South Carolina

    • Medical University of South Carolina, Charleston. 843-792-1869

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.